Home/Filings/4/0001235802-22-000136
4//SEC Filing

STANKOVICH THOMAS 4

Accession 0001235802-22-000136

CIK 0001427570other

Filed

Dec 19, 7:00 PM ET

Accepted

Dec 20, 4:35 PM ET

Size

9.9 KB

Accession

0001235802-22-000136

Insider Transaction Report

Form 4
Period: 2022-11-17
STANKOVICH THOMAS
Chief Financial Officer
Transactions
  • Sale

    Common Stock, $0.001 par value per share

    2022-12-01$0.15/sh5,144$778327,617 total
  • Award

    Common Stock, $0.001 par value per share

    2022-11-17+364,756697,517 total
  • Sale

    Common Stock, $0.001 par value per share

    2022-11-28$0.17/sh364,756$61,826332,761 total
  • Sale

    Common Stock, $0.001 par value per share

    2022-12-01$0.15/sh2,213$334325,404 total
Footnotes (3)
  • [F1]These shares were issued pursuant to a stock bonus granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
  • [F2]These shares were sold to cover taxes and fees in connection with the stock bonus.
  • [F3]On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

Issuer

ReShape Lifesciences Inc.

CIK 0001427570

Entity typeother

Related Parties

1
  • filerCIK 0001181166

Filing Metadata

Form type
4
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 4:35 PM ET
Size
9.9 KB